SYShirley P. Yu

Shirley P. Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shirley P. Yu has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A consumer co-designed community physical activity program for Australians living with osteoarthritis (CASCADE-OA): A randomised controlled trial protocol

    by Sarah Kobayashi, David J. Hunter, Leigh F. Callahan, Dawn Aitken, Christian J. Barton, Kim L. Bennell, Frances Daley, Jillian P. Eyles, Rana S. Hinman, Elena Losina, et al.


  • Open Access

    The Development and Usability Testing of the “OA Coach” Mobile Application to Support Individuals with Osteoarthritis: A Feasibility Study (Preprint)

    by Vicky Duong, Naomi Bloul, Jocelyn Bowden, Karen Bracken, Kate Bryce, Leticia Deveza, Jillian Eyles, Abdolhay Farivar, Robin Huang, Sarah Kobayashi, et al.

    BACKGROUND The OA Coach mobile application (app) was developed to support individuals with knee osteoarthritis (OA) to self-manage their condition. The app aims to fill a current gap in the OA mobile app field combining key features such as symptom tracking, objective activity tracking, educational modules, and encouragement notifications underpinned by behaviour change theory. OBJECTIVE The aim of this study was to describe the development of the OA Coach mobile app and assess its usability in a 6-week feasibility study. METHODS The app was designed in consultation with consumers, rheumatologists, physiotherapists and OA researchers. The app prototype contained four screens: 1) a home screen to track goals and activities; 2) a progress page; 3) a learning page with s self-directed modules; and 4) an inbox, for communication with the study team. For the feasibility study, 30 participants were recruited between March and April 2024 from a database of OA trial participants or through the Osteoarthritis Chronic Care Program at Royal North Shore Hospital, Sydney, Australia. Participants were eligible if they were aged ≥45 years old, had knee pain ≥ 4 on an 11-point numerical pain rating scale (NPRS) and knee stiffness lasting < 30 minutes in duration, or stiffness > 30 minutes and diagnosed with knee OA through a healthcare provider or radiographs. Participants were provided access to the app and asked to interact with the app daily for six weeks. Outcomes were assessed through online questionnaires or through mobile app data. The primary outcome was usability, assessed using the mHealth App Usability Questionnaire (MAUQ). Secondary outcomes included computer self-efficacy and osteoarthritis knowledge. Quantitative data was summarised descriptively. Qualitative feedback was collected through open-ended survey responses and discussed within the research team to improve the app. RESULTS A total of 30 participants completed the study. There was a 1:1 ratio of male to female participants, with an average (SD) age of 66.9 (9.1) years and a mean (IQR) pain level of 6.0 (1.8) on an 11-point NPRS. Twenty-nine responses from the MAUQ were available for analysis. Most statements scored > 5 out of 7 (“somewhat agree”), indicating that the app was easy to use. The mean (SD) satisfaction score of the app on the MAUQ was 4.7 (2.0) out of 7. Qualitative feedback from participants indicated the need for clear instructions on how to use and navigate the app, improved structure and integration of the exercise program, and improved tailoring of OA education and support. CONCLUSIONS Overall, the OA Coach app was well accepted by participants. Based on participant feedback, the app will be revised to improve aspects of clarity, ease of use, and personalisation. The updated app will be tested against other methods of care delivery in a randomised controlled trial. CLINICALTRIAL Australian and New Zealand Clinical Trials Registry, registry number: 12623001223628, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386764&isReview=true.

  • Open Access

    The Development and Usability Testing of the “OA Coach” Mobile Application to Support Individuals with Osteoarthritis: A Feasibility Study (Preprint)

    by Vicky Duong, Naomi Bloul, Jocelyn Bowden, Karen Bracken, Kate Bryce, Leticia Deveza, Jillian Eyles, Abdolhay Farivar, Robin Huang, Sarah Kobayashi, et al.

    Background: The OA Coach mobile app was developed to support individuals with knee osteoarthritis in self-managing their condition. The app aims to fill a current gap in the osteoarthritis mobile app field by combining key features such as symptom tracking, objective activity tracking, educational modules, and encouragement notifications underpinned by behavior change theory. Objective: The aim of this study was to describe the development of the OA Coach mobile app and assess its usability in a 6-week feasibility study. Methods: The app was designed in consultation with consumers, rheumatologists, physiotherapists, and osteoarthritis researchers. The app prototype contained four screens: (1) a home screen to track goals and activities, (2) a progress page, (3) a learning page with self-directed modules, and (4) an inbox for communication with the study team. For the feasibility study, 30 participants were recruited between March and April 2024 from a database of osteoarthritis trial participants or through the Osteoarthritis Chronic Care Program at Royal North Shore Hospital, Sydney, Australia. Participants were eligible if they were aged 45 years or older, had knee pain ≥4 on an 11-point numerical pain rating scale and knee stiffness lasting 30 minutes and diagnosed with knee osteoarthritis through a health care provider or radiographs. Participants were provided access to the app and asked to interact with it daily for 6 weeks. Outcomes were assessed through online questionnaires or through mobile app data. The primary outcome was usability, assessed using the mHealth App Usability Questionnaire (MAUQ). Secondary outcomes included computer self-efficacy and osteoarthritis knowledge. The quantitative data were summarized descriptively. Qualitative feedback was collected through open-ended survey responses and discussed within the research team to improve the app. Results: A total of 30 participants completed the study. There was a 1:1 ratio of male to female participants, with an average age of 66.9 (SD 9.1) years and a mean pain level of 6.0 (IQR 5.0-6.8) on an 11-point numerical pain rating scale. Twenty-nine responses from the MAUQ were available for analysis. Most statements scored >5 out of 7 (“somewhat agree”), indicating that the app was easy to use. The mean satisfaction score for the app on the MAUQ was 4.7 (SD 2.0) out of 7. Qualitative feedback from participants indicated the need for clear instructions on how to use and navigate the app, improved structure and integration of the exercise program, and improved tailoring of osteoarthritis education and support. Conclusions: Overall, the OA Coach app was well accepted by participants. Based on participant feedback, the app will be revised to improve aspects of clarity, ease of use, and personalization. The updated app will be tested against other methods of care delivery in a randomized controlled trial.

  • Open Access

    Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

    by Shirley P. Yu, Leticia A. Deveza, Virginia B. Kraus, Morten Karsdal, Anne-Christine Bay-Jensen, Jamie E. Collins, Ali Guermazi, Frank W. Roemer, Christoph Ladel, Venkatesha Bhagavath, et al.

    Background: To assess the prognostic value of short-term change in biochemical markers as it relates to bone marrow lesions (BMLs) on MRI in knee osteoarthritis (OA) over 24 months and, furthermore, to assess the relationship between biochemical markers involved with tissue turnover and inflammation and BMLs on MRI. Methods: Data from the Foundation for the National Institutes of Health OA Biomarkers Consortium within the Osteoarthritis Initiative (n = 600) was analyzed. BMLs were measured according to the MRI Osteoarthritis Knee Score (MOAKS) system (0–3), in 15 knee subregions. Serum and urinary biochemical markers assessed were as follows: serum C-terminal crosslinked telopeptide of type I collagen (CTX-I), serum crosslinked N-telopeptide of type I collagen (NTX-I), urinary CTX-Iα and CTX-Iβ, urinary NTX-I, urinary C-terminal cross-linked telopeptide of type II collagen (CTX-II), serum matrix metalloproteinase (MMP)-degraded type I, II, and III collagen (C1M, C2M, C3M), serum high sensitivity propeptide of type IIb collagen (hsPRO-C2), and matrix metalloproteinase-generated neoepitope of C-reactive protein (CRPM). The association between change in biochemical markers over 12 months and BMLs over 24 months was examined using regression models adjusted for covariates. The relationship between C1M, C2M, C3M, hsPRO-C2, and CRPM and BMLs at baseline and over 24 months was examined. Results: Increases in serum CTX-I and urinary CTX-Iβ over 12 months were associated with increased odds of changes in the number of subregions affected by any BML at 24 months. Increase in hsPRO-C2 was associated with decreased odds of worsening in the number of subregions affected by any BML over 24 months. C1M and C3M were associated with BMLs affected at baseline. Conclusions: Short-term changes in serum CTX-I, hsPRO-C2, and urinary CTX-Iβ hold the potential to be prognostic of BML progression on MRI. The association of C1M and C3M with baseline BMLs on MRI warrants further investigation.


  • Open Access

    Predictors of Placebo Response to Local (Intra‐Articular) Therapy In Osteoarthritis: An Individual Participant Data Meta‐Analysis

    by Shirley P. Yu, Marienke van Middelkoop, Leticia A. Deveza, Manuela L. Ferreira, Sita Bierma‐Zeinstra, Weiya Zhang, Ismaël Atchia, Fraser Birrell, Venkatsha Bhagavath, David J. Hunter

    Objective: We undertook this study to evaluate potential predictors of placebo response with intra‐articular (IA) injections for knee/hip osteoarthritis (OA) using individual participant data (IPD) from existing trials.Methods: Randomized placebo‐controlled trials evaluating IA glucocorticoid or hyaluronic acid published to September 2018 were selected. IPD for disease characteristics and outcome measures were acquired. Potential predictors of placebo response included participant characteristics, pain severity, intervention, and trial design. Placebo response was defined as at least a 20% reduction in baseline pain. Logistic regression models and odds ratios were computed as effect measures to evaluate patient and pain mechanisms and then pooled using a random effects model. Generalized mixed‐effect models were applied to intervention and trial characteristics.Results: Of 56 eligible trials, 6 shared data, and these were combined with the existing 4 OA Trial Bank studies, yielding 10 studies with IPD of 621 placebo participants for analysis. In the total placebo population, at short‐term follow‐up, the use of local anesthetic and ultrasound guidance were associated with reduced odds of placebo response. At midterm follow‐up, mid‐ to long‐term trial duration was associated with increased odds of placebo response, and worse baseline function scores were associated with reduced odds of a placebo response.Conclusion: The administration of local anesthetics or ultrasound guidance may reduce IA placebo response at short‐term follow‐up. At midterm follow‐up, participants with worse baseline function scores may be less likely to respond to IA placebo, and mid‐ to long‐term trial duration may enhance the placebo response. Further studies are required to corroborate these potential predictors of IA placebo response.


  • Open Access

    The OA Trial Bank: Update of individual patient data meta-analysis of intra-articular glucocorticoids in persons with knee and hip osteoarthritis

    by Shirley P. Yu, Marienke van Middelkoop, Manuela L. Ferreira, Leticia Deveza, Sita M.A. Bierma-Zeinstra, Venkatesha Venkatesha, David J. Hunter


  • Evaluating Osteoarthritis Management Programs: outcome domain recommendations from the OARSI Joint Effort Initiative

    by K.D. Allen, K. Huffman, R.J. Cleveland, M. van der Esch, J.H. Abbott, A. Abbott, K. Bennell, J.L. Bowden, J. Eyles, E.L. Healey, et al.


  • Responsiveness of an activity tracker as a measurement tool in a knee osteoarthritis clinical trial (ACTIVe-OA study)

    by Shirley P. Yu, Manuela L. Ferreira, Vicky Duong, Jimmy Caroupapoullé, Nigel K. Arden, Kim L. Bennell, David J. Hunter


  • What is the selection process for osteoarthritis pharmacotherapy?

    by Shirley P. Yu, David J. Hunter

    Osteoarthritis is the most prevalent joint condition that continues to increase with an ever-aging population and the rising tide of obesity. There are multiple recommendations/guidelines for the management of osteoarthritis. The basis of management should focus on self-management and education, lifestyle modifications, exercise and when appropriate, weight loss. Pharmacotherapy is targeted toward pain palliation with no agents available presently to target prevention and disease modification. The selection of pharmacotherapy should be tailored to the individual, taking into account of personal preferences and interactions with underlying co-morbidities. This editorial provides a guide to the selection process of presently available pharmacotherapy in osteoarthritis.


  • Development of a core capability framework for qualified health professionals to optimise care for people with osteoarthritis: an OARSI initiative

    by R.S. Hinman, K.D. Allen, K.L. Bennell, F. Berenbaum, N. Betteridge, A.M. Briggs, P.K. Campbell, L.E. Dahlberg, K.S. Dziedzic, J.P. Eyles, et al.